Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. 2013

Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
Key Laboratory of Natural Resources and Functional Molecules of the Changbai Mountain, Affiliated Ministry of Education, Yanbian University College of Pharmacy, Yanji 133002, PR China.

Three series of rhodanine derivatives bearing a quinoline moiety (6a-h, 7a-g, and 8a-e) have been synthesized, characterized, and evaluated as antibacterial agents. The majority of these compounds showed potent antibacterial activities against several different strains of Gram-positive bacteria, including multidrug-resistant clinical isolates. Of the compounds tested, 6g and 8c were identified as the most effective with minimum inhibitory concentration (MIC) values of 1 μg/mL against multidrug-resistant Gram-positive organisms, including methicillin-resistant and quinolone-resistant Staphylococcus aureus (MRSA and QRSA, respectively). None of the compounds exhibited any activity against the Gram-negative bacteria Escherichia coli 1356 at 64 μg/mL. The cytotoxic activity assay showed that compounds 6g, 7g and 8e exhibited in vitro antibacterial activity at non-cytotoxic concentrations. Thus, these studies suggest that rhodanine derivatives bearing a quinoline moiety are interesting scaffolds for the development of novel Gram-positive antibacterial agents.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011804 Quinolines
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012236 Rhodanine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus

Related Publications

Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
January 2018, European journal of medicinal chemistry,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
June 2013, Archiv der Pharmazie,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
May 2015, Drug research,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
December 2012, Bioorganic & medicinal chemistry letters,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
December 2013, Bioorganic & medicinal chemistry letters,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
December 2014, Archiv der Pharmazie,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
April 2010, European journal of medicinal chemistry,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
June 2017, Molecules (Basel, Switzerland),
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
January 2019, European journal of medicinal chemistry,
Meng Guo, and Chang-Ji Zheng, and Ming-Xia Song, and Yan Wu, and Liang-Peng Sun, and Yin-Jing Li, and Yi Liu, and Hu-Ri Piao
August 2014, European journal of medicinal chemistry,
Copied contents to your clipboard!